Development of lupic anticoagulant during combination therapy in a patient with chronic hepatitis C

J Hepatol. 2001 Jun;34(6):965-7. doi: 10.1016/s0168-8278(01)00024-1.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Comment

MeSH terms

  • Antiviral Agents / adverse effects
  • Drug Therapy, Combination
  • Female
  • Hepatitis C, Chronic / blood
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / immunology*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / adverse effects
  • Lupus Coagulation Inhibitor / metabolism*
  • Middle Aged
  • Partial Thromboplastin Time
  • Recombinant Proteins
  • Ribavirin / adverse effects

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Lupus Coagulation Inhibitor
  • Recombinant Proteins
  • Ribavirin